Magdalena Staniszewska

Mrs. Magdalena Staniszewska


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MSMagdalena Staniszewska
Magdalena Staniszewska
PCPedro Fragoso Costa
Pedro Fragoso Costa
MEMatthias Eiber
Matthias Eiber
JKJasmin M. Klose
Jasmin M. Klose
JWJasmin Wosniack
Jasmin Wosniack
Janette IkingJanette Iking
Janette Iking
Prostate-specific membrane antigen (PSMA)-directed radioligand therapy (RLT) prolongs overall survival in men with metastatic castration-resistant prostate cancer (mCRPC). However, men with low PSMA expression are excluded from RLT. We explored the effect of androgen receptor blockade with enzalutamide on PSMA expression. Assessment of PSMA and androgen receptor (AR) expression on the human PC cell lines 22Rv1, C4-2, and LNCaP by immunohistochemistry and flow cytometry revealed low (22Rv1) and high (C4-2 and LNCaP) PSMA expression, and high, comparable AR positivity. Treatment with enzalutamide increased PSMA levels in 22Rv1, C4-2, and LNCaP (2.2/2.3/2.6-fold, p = 0.0005/0.03/0.046) after one week compared to DMSO-treated controls as assessed by flow cytometry. NOD/Scid mice bearing 22Rv1 tumors were treated with enzalutamide for two weeks. Positron emission tomography/computed tomography (PET/CT) demonstrated higher tumor uptake of 68Ga-PSMA after enzalutamide treatment (p = 0.004). Similarly, a clinical case with low baseline PSMA avidity demonstrated increased uptake of 68Ga-PSMA after enzalutamide on PET/CT and post-therapeutic 177Lu-PSMA scintigraphy in a patient with mCRPC. Enzalutamide induced PSMA expression in the 22Rv1 xenograft model and in an mCRPC patient, both with low baseline tumoral PSMA levels. Therefore, enzalutamide pre-treatment might render patients with low PSMA expression eligible for 177Lu-PSMA RLT.

19 February 2021 in Biomedicines
Verified
Journal Article
Open access
PDF file
Janette IkingJanette Iking
Janette Iking
MSMagdalena Staniszewska
Magdalena Staniszewska
LKLukas Kessler
Lukas Kessler
JKJasmin M. Klose
Jasmin M. Klose
KLKatharina Lückerath
Katharina Lückerath
CRChristoph Rischpler
Christoph Rischpler
The impact of inflammation on the outcome of many medical conditions such as cardiovascular diseases, neurological disorders, infections, cancer, and autoimmune diseases has been widely acknowledged. However, in contrast to neurological, oncologic, and cardiovascular disorders, imaging plays a minor role in research and management of inflammation. Imaging can provide insights into individual and temporospatial biology and grade of inflammation which can be of diagnostic, therapeutic, and prognostic value. There is therefore an urgent need to evaluate and understand current approaches and potential applications for imaging of inflammation. This review discusses radiotracers for positron emission tomography (PET) that have been used to image inflammation in cardiovascular diseases and other inflammatory conditions with a special emphasis on radiotracers that have already been successfully applied in clinical settings.

1 May 2021 in Nuclear Medicine and Biology
Verified
Journal Article
Open access
MSMagdalena Staniszewska
Magdalena Staniszewska
Janette IkingJanette Iking
Janette Iking
KLKatharina Lückerath
Katharina Lückerath
BHBoris Hadaschik
Boris Hadaschik
KHKen Herrmann
Ken Herrmann
WFWolfgang P. Fendler
Wolfgang P. Fendler
Metastatic castration resistant prostate cancer (mCRPC) is a highly lethal disease. Several novel therapies have been assessed in the past years. Targeting DNA damage response (DDR) pathways in prostate cancer became a promising treatment strategy and olaparib and rucaparib, Poly(ADP-ribose) polymerase (PARP) inhibitors, have been approved for patients carrying mutations in homologous recombination (HR) repair pathways. Other DDR inhibitor targets, such as ATM, ATR, CHK1, CHK2, and WEE1 are under extensive investigation. Additionally, molecular radiotherapy (MRT) including [177Lu]Lu-PSMA, [225Ac]Ac-PSMA, [223Ra]Ra-dichloride, [153Sm]-EDTMP, [188Re]Re-HDMP and GRPR-targeted MRT treat cancer through internal ionizing radiation causing DNA damage and demonstrate promising efficacy in clinical trials. In the field of immunotherapy, checkpoint inhibition as well as sipuleucel-T and PROSTVAC demonstrated only limited efficacy in mCRPC when used as monotherapy. This review discusses recent therapeutic strategies for mCRPC highlighting the need for rational combination of treatment options.

16 March 2021 in eLife
Verified
Journal Article
Open access
ASArne Sahm
Arne Sahm
MPMatthias Platzer
Matthias Platzer
PKPhilipp Koch
Philipp Koch
YHYoshiyuki Henning
Yoshiyuki Henning
MBMartin Bens
Martin Bens
PDPhilip Dammann
Philip Dammann
Sexual activity and/or reproduction are associated with a doubling of life expectancy in the long-lived rodent genusFukomys. To investigate the molecular mechanisms underlying this phenomenon, we analyzed 636 RNA-seq samples across 15 tissues. This analysis suggests that changes in the regulation of the hypothalamic–pituitary–adrenal stress axis play a key role regarding the extended life expectancy of reproductive vs. non-reproductive mole-rats. This is substantiated by a corpus of independent evidence. In accordance with previous studies, the up-regulation of the proteasome and so-called ‘anti-aging molecules’, for example, dehydroepiandrosterone, is linked with enhanced lifespan. On the other hand, several of our results are not consistent with knowledge about aging of short-lived model organisms. For example, we found the up-regulation of the insulin-like growth factor 1/growth hormone axis and several other anabolic processes to be compatible with a considerable lifespan prolongation. These contradictions question the extent to which findings from short-lived species can be transferred to longer-lived ones.

6 January 2022 in Journal of Nuclear Medicine
Verified
Journal Article
Closed access
PDF file
JKJasmin Mona Klose
Jasmin Mona Klose
JWJasmin Wosniack
Jasmin Wosniack
Janette IkingJanette Iking
Janette Iking
MSMagdalena Staniszewska
Magdalena Staniszewska
FZFadi Zarrad
Fadi Zarrad
WFWolfgang Fendler
Wolfgang Fendler
Introduction: The NETTER-1, VISION, and TheraP trials prove efficacy of repeat intravenous (i.v.) application of small radioligands. Application by subcutaneous (s.c.), intraperitoneal (i.p.), or oral (p.o.) access are important alternatives and may yield comparable or favorable organ and tumor radioligand uptake. Here, we assess organ and tumor biodistribution for various radioligand application routes in healthy mice and models of somatostatin receptor (SSTR)-, prostate-specific membrane antigen (PSMA)-, and fibroblast activation protein (FAP)- expressing cancer. Methods: Healthy and tumor-bearing male C57BL/6 or NOD SCID Gamma mice, respectively, were applied with a mean of 6.0±0.5 MBq 68Ga DOTATOC (RM1-SSTR allograft), 5.3±0.3 MBq 68Ga-PSMA11 (RM1-PSMA allograft) or 4.8±0.2 MBq 68Ga-FAPI46 (HT1080 FAP xenograft) i.v., i.p., s.c. or p.o.. In vivo positron emission tomography and ex vivo biodistribution in tumor, organs, and at the injection site were assessed up to 5h post injection (p.i.). Healthy mice were monitored for up to 7 days after the last scan for signs of stress or adverse reactions. Results: After i.v., i.p. and s.c. radioligand administration, average residual activity at the injection site was <17%IA/g (1h p.i.), <10%IA/g (2h p.i.) and ≤4%IA/g (4h p.i.) for all radioligands. Following oral administration ≥50%IA/g remained within the intestines until 4h p.i.. Biodistribution in organs of healthy mice was nearly equivalent following i.v., i.p., and s.c. application at 1h p.i. and all subsequent timepoints (≤1%IA/g for liver, blood and bone marrow; 11.2±1.4%IA/g for kidneys). In models for SSTR-, PSMA- and FAP-expressing cancer, tumor uptake was higher or equivalent for i.p./s.c. versus i.v. injection at 5h p.i. (ex vivo): SSTR: 7.2±1.0%IA/g (P = 0.0197) / 6.5±1.3%IA/g (P = 0.0827) versus 2.9±0.3%IA/g; PSMA: 3.4±0.8%IA/g (P = 0.9954) / 3.9±0.8%IA/g (P = 0.8343) versus 3.3±0.7%IA/g and FAP: 1.1±0.1%IA/g (P = 0.9805) / 1.1±0.1%IA/g (P = 0.7446) versus 1.0±0.2%IA/g. Conclusion: In healthy mice, biodistribution of small theranostic ligands following i.p. or s.c. application is nearly equivalent compared to i.v. injection. S.c. administration resulted in highest absolute SSTR tumor and tumor-to-organ uptake as compared to the i.v. route, warranting further clinical assessment.

31 May 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
SSStephan Settelmeier
Stephan Settelmeier
ZVZohreh Varasteh
Zohreh Varasteh
MSMagdalena Staniszewska
Magdalena Staniszewska
ABAnna-Lena Beerlage
Anna-Lena Beerlage
FZFadi Zarrad
Fadi Zarrad
UHUlrike Hendgen-Cotta
Ulrike Hendgen-Cotta
The cardiac bioavailability of peptide drugs that inhibit harmful intracellular protein–protein interactions in cardiovascular diseases remains a challenging task in drug development. This study investigates whether a non-specific cell-targeted peptide drug is available in a timely manner at its intended biological destination, the heart, using a combined stepwise nuclear molecular imaging approach. An octapeptide (heart8P) was covalently coupled with the trans-activator of transcription (TAT) protein transduction domain residues 48–59 of human immunodeficiency virus-1 (TAT-heart8P) for efficient internalization into mammalian cells. The pharmacokinetics of TAT-heart8P were evaluated in dogs and rats. The cellular internalization of TAT-heart8P-Cy(5.5) was examined on cardiomyocytes. The real-time cardiac delivery of 68Ga-NODAGA-TAT-heart8P was tested in mice under physiological and pathological conditions. Pharmacokinetic studies of TAT-heart8P in dogs and rats revealed a fast blood clearance, high tissue distribution, and high extraction by the liver. TAT-heart-8P-Cy(5.5) was rapidly internalized in mouse and human cardiomyocytes. Correspondingly, organ uptake of hydrophilic 68Ga-NODAGA-TAT-heart8P occurred rapidly after injection with an initial cardiac bioavailability already 10 min post-injection. The saturable cardiac uptake was revailed by the pre-injection of the unlabeled compound. The cardiac uptake of 68Ga-NODAGA-TAT-heart8P did not change in a model of cell membrane toxicity. This study provides a sequential stepwise workflow to evaluate the cardiac delivery of a hydrophilic, non-specific cell-targeting peptide. 68Ga-NODAGA-TAT-heart8P showed rapid accumulation in the target tissue early after injection. The implementation of PET/CT radionuclide-based imaging methodology as a means to assess effective and temporal cardiac uptake represents a useful and critical application in drug development and pharmacological research and can be extended to the evaluation of comparable drug candidates.